摘要
目的探讨吡格列酮联合前列地尔治疗糖尿病肾病(DN)的临床效果。方法选择2015年11月~2017年2月在南方医科大学珠江医院治疗的DN患者98例,按随机数字表法分为治疗组和对照组,每组各49例。治疗组采用吡格列酮联合前列地尔治疗,对照组采用吡格列酮治疗,持续治疗6个月。分析两组患者治疗前后高敏C反应蛋白(HS-CRP)、糖化血红蛋白(Hb A1c)、血肌酐(Scr)、尿素氮(BUN)、血清胱抑素C(Cys-C)、24 h尿微量白蛋白(24 h UAE)、血清脂肪特异性丝氨酸蛋白酶抑制剂(Vaspin)、胰岛素抵抗指数(HOMA-IR)。结果治疗前,两组患者HS-CRP、比较,差异无统计学意义(P>0.05)。治疗6个月后,两组上述指标均较治疗前有所改善,且治疗组优于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论吡格列酮联合前列地尔治疗DN的临床效果较好,值得临床上应用。
Objective To investigate the clinical effect of Pioglitazone combined with Alprostadil in treating diabetic nephropathy （DN）. Methods From May 2015 to February 2017, 98 patients with DN in Zhujiang Hospital of Southern Medical University were divided into treatment group and control group by random number table, with 49 cases in each group. The treatment group was treated with Pioglitazone and Alprostadil, while the control group was treated with Pioglitazone, continuous treatment for 6 months. The levels of high sensitivity C-reactive protein （HS-CRP）, glycosylated hemoglobin （HbA,c）, serum creatinine （Scr）, urea nitrogen （BUN）, serum cystatin C （Cys-C）, 24-hour urinary albumin （24 h UAE）, serum adipose-specific serine protease inhibitor （Vaspin）, insulin resistance index （HOMA-IR） were ana- lyzed before and after treatment in both groups. Results Before treatment, there were no statistically significant differences in the levels of HS-CRP, HbA1cn, Scr, BUN, Cys-C, Vaspin, HOMA-IR, 24 h UAE between the two groups （P 〉 0.05）. Six month after treatment, all of these indicators were improved in the two groups, and those of the treatment group were better than those of the control group, with statistically significant difference （P 〈 0.05）. There was no statistically significant difference in the adverse effects rate between the two groups （P 〉 0.05）. Conclusion The clinical effect of Pioglitazone combined with Alprostadil in treating diabetic nephropathy is better, which is worthy of clinical application.
出处
《中国医药导报》
CAS
2017年第36期101-103,共3页
China Medical Herald
基金
广东省医学科学技术研究基金(B2013380)
